• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

head and neck squamous cell carcinoma (HNSCC) - Articles and news items

AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold

Industry news / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly….

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

Merck releases new data for Keytruda at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells…

FDA accepts sBLA for Keytruda in head and neck cancer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy…

First patient enrolled in Phase II trial of ImmunoPulse IL-12

Industry news / 17 June 2015 / Victoria White

OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +